From the Division of Epidemiology (M.M.M.), Department of Health Sciences Research, College of Medicine, Mayo Clinic, Rochester, MN; Department of Psychiatry, Division of Geriatric Psychiatry and Neuropsychiatry (N.J.H., P.V.R., C.G.L.), Department of Neurology (V.V.R.B., N.J.H., M.A.), Center on Aging and Health (J.X., S.Y., V.V., G.H., M.C.C.), Department of Medicine, Division of Geriatric Medicine & Gerontology (S.Y.), and Department of Surgical Trials and Outcomes Research (E.B.S.), Johns Hopkins University School of Medicine, Baltimore, MD; Mailman School of Public Health (L.P.F.), Columbia University, New York, NY; and Departments of Mental Health (V.V., M.C.C.) and Biostatistics (K.B.-R.), Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD.
First Published July 18, 2012.
Previous version (July 18, 2012 - 13:01).
Dr. Mielke also received research support from the George and Cynthia Mitchell Foundation. Role: co-PI, Date: 07/01/2007-06/30/2010.
R01 AA0017408 (Haughey, PI). 9/27/07 – 8/31/12 NIAAA Interaction of Alcohol with HIV-Protein Using in vitro and in vivo models of HIV-dementia, we propose to determine the mechanisms of how alcohol dysregulates neuronal function in acute, chronic and withdrawal conditions. R01 MH077542 (Haughey, PI) 9/17/07 – 5/31/12 NIMH Dysfunctions of Sphingolipid and Sterol Metabolism in HIV-Dementia In this application we will test the central hypothesize that the HIV-1 proteins gp120 and Tat alter the sphingolipid composition of neuronal membranes and cluster post-translationally modified NMDA receptors in lipid rafts. R21AG034849-01 (Haughey, PI)4/1/10 – 3/31/12 NIA Perturbation of Amyloid Processing in HAND The goals of this application are to determine the mechanisms by which the HIV coat protein gp120 promotes aberrant amyloid processing and amyloid-beta deposition. 2 P30 MH075673-06 (McArthur)7/1/11 – 6/30/16 NIMH Center for novel therapeutics for HIV-associated cognitive disorders Role: Director of Surrogate Markers Core, Co-Director Therapeutics Core. U01AG037526-01 (Mielke, PI) 7/1/10 – 6/30/151 Mayo Clinic/NIA Longitudinal Study of Lipids and APOE in the Development of AD and AD Pathology The overall aim of the proposed study is to examine, in the 50-year Baltimore Longitudinal Study of Aging, whether plasma lipids measured in mid-life (sphingolipids, gangliosides, fatty acids, cholesterol and cholesterol esters) modify the association between APOE and cognitive decline, clinical onset of mild cognitive impairment or AD, and neuroimaging measures of brain atrophy and brain pathology. Role: Co-I.
NIH Grant R37AG19905 in the role of Principal Investigator for years covering 2001-present.
Commercial: Elan, Lilly, Avanir, Forest, Takeda, Pfizer, NFLPA. Non-profit DSMB: Indiana University.
No compensation: International Review of Psychiatry, International Psychogeriatrics, Psychosomatics, ADRD.
Elan, Lilly, Takeda, Pfizer, NFL Benefits.
NIH, NIMH, NIA, Alzheimer’s Association.